|
Tyzeka
(telbivudine)
Articles on Tyzeka (telbivudine)
Indication
TYZEKA® is indicated for the treatment of chronic hepatitis
B (CHB) in adult patients with evidence of viral replication and
either evidence of persistent elevations in serum aminotransferases
(ALT or AST) or histologically active disease.
Articles on Tyzeka (telbivudine) for the Treatment of Hepatitis
B
Telbivudine
Label Adds Resistance Warning
4-05-2011
Telbivudine
and Elective Cesarean Section Help Prevent Mother-to-child Hepatitis
B Transmission
11-09-2010
How Long Do Chronic Hepatitis B
Patients Need to be Treated
to Sustain HBeAg Seroconversion?
6-25-2010
Telbivudine
(Tyzeka) Produces Better Outcomes than Lamivudine in
Hepatitis B Patients with Decompensated Cirrhosis
4-30-2010
Long-term Data
Show Telbivudine (Tyzeka) Suppresses
HBV Viral Load and Leads to HBeAg Clearance in Chronic Hepatitis
B Patients
11-20-2009
Predictors
of Good Response to Telbivudine (Tyzeka)
for Chronic Hepatitis B
8-04-2009
Telbivudine
(Tyzeka) Continues to Produce Good Results for Chronic
Hepatitis B Patients after 3 Years
5-08-2009
Telbivudine
(Tyzeka) May Be Effective for Chronic Hepatitis B Treatment
after Failure of Adefovir (Hepsera)
3-10-2009
GLOBE
Trial 2-Year Data Shows Telbivudine (Tyzeka) Is More Effective
than Lamivudine (Epivir-HBV) for
Chronic Hepatitis B
2-27-2009
Does
Telbivudine (Tyzeka) Have Activity
Against HIV?
2-17-2009
Canadian
Health Officials Warn against Use of Tebivudine
(Tyzeka/Sebivo) in Combination with Interferons
3-18-2009
|
